Yellow Fever Vaccine

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Yellow Fever Vaccine
   1. Pharmacist Assessment Report
   2. Yellow Fever Vaccine: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Yellow Fever Vaccine: Known uses and market status in Canada

Summary

The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Yellow Fever Vaccine, so there is currently no new predicted indication. The uses recorded for this drug are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
00428833	YF-VAX		Valid

Safety Considerations

Drug Interactions: The interaction query completed with 100 recorded interactions. Most listed entries are rated Major:

• Corticosteroids: hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone (all Major); budesonide and ophthalmic triamcinolone (Moderate)
• Immunosuppressants and immune-modulating agents: tacrolimus, dupilumab, corticotropin, levamisole (all Major)
• Cytotoxic or antimetabolite agents: mercaptopurine, trimetrexate, dexrazoxane (all Major)
• Radiopharmaceuticals and radioimmunotherapies: iobenguane (I-131), ibritumomab tiuxetan, tositumomab, tositumomab (I-131) (all Major)

These interactions are consistent with the general concern of giving a live vaccine to patients with suppressed immunity. For the full safety profile, please refer to the package insert.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---